Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals | Zendy

Matthew E. Falagas | Zendy; Tilemachos Skalidis | Zendy; Konstantinos Z. Vardakas | Zendy; N.J. Legakis | Zendy

Open Access

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

Author(s) -

Matthew E. Falagas,

Tilemachos Skalidis,

Konstantinos Z. Vardakas,

N.J. Legakis

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx049

Subject(s) - colistin , microbiology and biotechnology , acinetobacter baumannii , tigecycline , enterobacter cloacae , biology , cephalosporin , cefepime , aztreonam , klebsiella pneumoniae , ceftazidime , pseudomonas aeruginosa , broth microdilution , meropenem , enterobacter , antimicrobial , imipenem , antibiotics , bacteria , antibiotic resistance , minimum inhibitory concentration , escherichia coli , biochemistry , genetics , gene

Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research